Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.

CONCLUSION: Palbociclib has limited single-agent activity in gastroesophageal tumors.
PMID: 32692450 [PubMed - as supplied by publisher]

Source: The Oncologist - July 20, 2020 Category: Cancer & Oncology Authors: Karasic T, O'Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, d'Entremont TS, Gallagher M, Zhang PJ, O'Dwyer PJ Tags: Oncologist Source Type: research